Psychiatr. pro Praxi, 2009; 10(3): 122-124

Atypical antipsychotics in the augmentation of antidepressants in the treatment of depressive disorder

MUDr. Martin Bareš
Psychiatrické centrum Praha, 3. LF UK, Praha

Depressive disorder is a relatively common disease in the population. Lifetime prevalence of major depression is 5–12 % in men and

9–26 % in women. Only 20–30 % patients treated with first antidepressant achieves remission. The use of atypical antipsychotics in the

augmentation of antidepressant treatment is modern and often used method in the treatment of resistant depression. The authors

comment the results of double-blind studies in this topic and discuss problem areas of this type of treatment.

Keywords: atypical antipsychotics, depressive disorder, treatment, augmentation.

Published: May 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Bareš M. Atypical antipsychotics in the augmentation of antidepressants in the treatment of depressive disorder. Psychiatr. praxi. 2009;10(3):122-124.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L. et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006; 163(1): 28-40. Go to original source... Go to PubMed...
    2. Anderson IM, Ferrier IN, Baldwin RC, Cowen PJ, Howard L, Lewis G, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol 2008; 22(4): 343-396. Go to original source... Go to PubMed...
    3. Bauer M, Bschor T, Pfennig A, Whybrow PC, Angst J, Versiani M, et al. WFSBP Task Force on Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders in primary care. World J Biol Psychiatry 2007; 8(2): 67-104. Go to original source... Go to PubMed...
    4. Valenstein M, McCarthy JF, Austin KL, Greden JF, Young EA, Blow FC. What happened to lithium? Antidepressant augmentation in clinical settings. Am J Psychiatry 2006; 163(7): 1219-1225. Go to original source...
    5. Bareš M, Hrdlička M, Propper L. Atypická neuroleptika v léčbě poruch nálady. Čes a slov Psychiat 1998; 94(1): 39-44.
    6. American Psychiatric Association. Guideline watch and Practice guideline for the treatment of patients with major depressive disorder, second edition. In: American Psychiatric Associations. Practice guidelines for the treatment of psychiatric disorders. Compendium, 2006. American Psychiatric Asssociation 2006: 747-840.
    7. Fountoulakis KN, Nimatoudis I, Iacovides A, Kaprinis G. Offlabel indications for atypical anitpsychotics: a systematic review. Ann Gen Hosp Psychiatry 2004; 3: 4. Go to original source... Go to PubMed...
    8. Shelton RC, Papakostas GI. Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder. Acta Psychiatr Scand 2008; 117(4): 253-259. Go to original source... Go to PubMed...
    9. Shelton RC, Tollefson GD, Tohen M, Stahl S, Gannon KS, Jacobs TG, et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001; 158(1): 131-134. Go to original source... Go to PubMed...
    10. Shelton RC, Williamson DJ, Corya SA, Sanger TM, Van Campen LE, Case M, Briggs SD, Tollefson GD. Olanzapine/ fluoxetine combination for treatment - resistant depression: A controlled-study of SSRI and nortriptyline resistance. J Clin Psychiatry 2005; 66: 1289-1297. Go to original source... Go to PubMed...
    11. Corya SA, Williamson D, Sanger TM, Briggs SD, Case M, Tollefson G, et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Depression and anxiety 2006; 23(6): 364-372. Go to original source... Go to PubMed...
    12. Thase ME, Corya SA, Osuntokun O, Case M, Henley DB, Sanger TM, et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. J Clin Psychiatry 2007; 68(2): 224-236. Go to original source... Go to PubMed...
    13. Ostroff RB, Nelson JC. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J Clin Psychiatry 1999; 60(4): 256-259. Go to original source... Go to PubMed...
    14. Rapaport MH, Gharabawi GM, Canuso CM, Mahmoud R, Keller MB, Bosie CA, et al. Effects of risperidone augmentation in patiens with treatment-resistant depression: results of open label treatment followed by double-blind continuation. Neuropsychpharmacology 2006; 31: 2505-2513. Go to original source... Go to PubMed...
    15. Alexopoulos GS, Canuso CM, Gharabawi GM, Bossie CA, Greenspan A, Turkoz I, et al. Placebo-controlled study of relapse prevention with risperidone augmentation in older patients with resistant depression. Am J Geriatr Psychiatry 2008; 16(1): 21-30. Go to original source... Go to PubMed...
    16. Mahmoud RA, Pandina GJ, Turkoz I, Kosik-Gonzalez C, Canuso CM, Kujawa MJ, et al. Risperidone for treatment-refractory major depressive disorder. A randomized trial. Ann Intern Med 2007; 147(9): 593-602. Go to original source... Go to PubMed...
    17. Keitner GI, Garlow SJ, Ryan CE, Ninan PT, Solomon DA, Nemeroff CB, et al. A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-totreat unipolar, non-psychotic major depression. J Psych Res 2008; doi: 10.1016/j.jpsychires. 2008; 05: 003.
    18. Dunner DL, Amsterdam JD, Shelton RC, Loebel A, Romano SJ. Efficacy and tolerability of adjunctive ziprasidone in treatmentresistant depression: a randomized, open-label, pilot study. J Clin Psychiatry 2007; 68(7): 1071-1077. Go to original source... Go to PubMed...
    19. Papakostas GI, Petersen TJ, Nierenberg AA, Murakami JL, Alpert JE, Rosenbaum JF. et al. Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. J Clin Psychiatry 2004; 65(2): 217-221. Go to original source... Go to PubMed...
    20. Berman RM, Marcus RN, Swanink R, McQuaude RD, Carson WH, Corey-Lisle PK, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2007; 68(6): 843-853. Go to original source... Go to PubMed...
    21. Smeraldi E. Amisulpride versus fluoxetine in patients with dysthymia or major depression in partial remission. A doubleblind, comparative study. J Affect Disord 1998; 48(1): 47-56. Go to original source... Go to PubMed...
    22. Papakostas GI, Shelton RC, Smith J, Fava M. Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis. J Clin Psychiatry 2007; 68(6): 826-831. Go to original source... Go to PubMed...
    23. Bareš M, Novák T. Depresivní poruha. In: Seifertová D, Praško J, Horáček J, Höschl C. (eds.) Postupy v léčbě psychických poruch. Algoritmy České neuropsychiatrické společnosti. Academia Medica Pragensis 2008: 103-130.

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.